Anti-HA Antibody Market Size & Share, by Type (IgM, IgG, IgA); Application (Therapeutic, Research, Diagnostic); End-User (Hospitals, Diagnostic Centers, Research Institutes, Biopharmaceutical Companies); Distribution Channel (Direct Sales, Distributors) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5461
  • Published Date: Dec 18, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Anti-HA Antibody Market size is expected to reach USD 5 Billion by the end of 2036, growing at a CAGR of 7% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of anti-HA antibody crossed around USD 1 Billion. The prevalence of influenza infection across the world is anticipated to primarily wheel the market to grow. A calculated 1 billion people internationally are infected by seasonal influenza yearly. Out of those 1 billion, about 3-5 million people have a massive case of flu each year. Across the globe, a calculated 290,000 – 650,000 deaths appear because of flu each year.  The World Health Organization has international programs that supervise influenza activity around member countries and follow international trends, spread, intensity, and influence of influenza.

Another factor that is estimated to highly contribute to the rapid growth of the anti-HA antibody market during the forecast period is its demand to cure influenza-infected patients worldwide. Oseltamivir can limit the average duration of influenza disorder by 1.3 days and considerably limits indications compared to placebo if provided within 48 hr of indication onset. In a prophylactic study, oseltamivir dropped rates of influenza infection 5-fold from 5% (25/519) for the placebo (an anti-HA antibody drug) group to 1% (6/520) for the oseltamivir-dealt group. Seasonal influenza vaccines have focused on producing nullifying anti-HA antibodies for security since licensure. In recent years, anti-NA antibodies have been accepted as an additional correlate of protection. While HA and NA antigenic transformations appeared inharmoniously, the anti-HA and anti-NA antibody profiles have seldom been assessed in parallel at the singular level, because of the restricted wisdom of NA antigenic transformations.


Anti-HA Antibody Market
Get more information on this report: Request Free Sample PDF


Anti-HA Antibody Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

∼7%

Base Year Market Size (2023)

~USD 1 Billion

Forecast Year Market Size (2036)

~USD 5 Billion

Regional Scope

  • North America (North America, Canada, Mexico)
  • Europe (Germany, Spain, UK, France, Italy, Russia, Others)
  • Asia Pacific (Japan, China, India, Australia, Others)
  • Middle East and Africa (South Africa, UAE, Others)
  • Latin America (Brazil, Argentina, Others)
Get more information on this report: Request Free Sample PDF

Anti-HA Antibody Sector: Growth Drivers and Challenges

Market-Growth-Drivers

Growth Drivers

  • Extensive Use as A General Antibody Epitope Tag- HA (hemagglutinin) tag is taken from the human influenza virus HA protein. It is well-attributed and is implemented widely as a general antibody epitope tag. The HA tag is taken from the HA molecule comparable to amino acids 98-106 and has been widely implemented as a general epitope tag in expression vectors. Many recombinant proteins have been planned to communicate to the HA tag, which does not interfere with the bioactivity or the allotment of the recombinant protein. This tag facilitates the detection, isolation, and purification of the proteins.
  • Excessive Demand for Therapeutic Antibodies - Therapeutic antibodies have become the dominant class of new drugs advanced in current years. Over the past five years, antibodies have turned into the best-selling medications in the pharmaceutical market, and in 2023, eight of the top ten highly successful medications globally were biologics. Vital modifications in antibody engineering done over the past decade have increased the protection and effectiveness of therapeutic antibodies. These advancements, as well as a greater knowledge of the immunomodulatory properties of antibodies, have created the way for the next generation of new and modified antibody-dependent medications for the therapy of human diseases.
  • Reliable Techniques of the Antibodies to Treat Influenza Viruses - HA tag antibodies give a reliable technique for the spotting and refinement of tagged aimed proteins without a protein-definite antibody or probe. Invitrogen HA tag antibodies faithfully spot recombinant HA-tagged proteins and every antibody is confirmed for implementation in multiple uses. Antibodies to HA can be implemented to study possible objectives for antiviral medications because of their main roles in the beginning stages of infection: receptor binding and the combination of virus and cell membranes. They are antigen-canceling molecules, generated by plasma B-cells in the body, that secure individuals by damaging pathogens and prohibiting their propagation. The primary functions executed by antibodies are neutralization, opsonization, stimulation of the supplement pathway, and antibody-dependent cell-referred cytotoxicity.

Challenges

  • Delay in Approval of the Anti-HA Antibody Drugs - Drug lag, the procrastination between the first international regulatory approval and acceptance by the national health authorities in other countries, influences the availability of medications. For instance, let's talk about Canada’s drug approval technique, if delivered under the standard technique, Health Canada has an aim timeline of 300 days to answer to the healthcare and pharmaceutical agency. However, this aim is not always reached while in practice. Of all new medication submissions filed in recent years, only 33% got an answer within the target. In fact, 18% took more than a year to investigate, and approximately 5% took over two years. On the whole, the standard investigation techniques lasted 335 days. Researchers have decided just how many lives are lost when efficient experimental drugs are not licensed immediately. To redeem costs, a lot of governments currently delayed the acceptance of seven new medicines suggested by the Pharmaceutical Benefits Advisory Committee (PBAC) for up to seven months.
  • Several Side Effects of the Anti-HA Antibody Drugs
  • Lapse of Patent of Various Effective Anti-HA Antibody Drugs


Anti-HA Antibody Segmentation

Type (IgM, IgG, IgA)

The IgM segment in the anti-HA antibody market is expected to hold 47% of the revenue share during the forecast period owing to the implementation of this type of anti-HA antibody in different medications. For instance, in mice, a singular intranasal dose of IgM-14 at 0.044 mg per kg body weight provides prophylactic efficiency and a single dose at 0.4 mg per kg provides therapeutic efficiency against SARS-CoV-2. IgM-14, but not IgG-14, also provides powerful therapeutic protection against the P.1 and B.1.351 variants.  IgM anti-HA antibodies are mainly oriented against the HA molecule itself and can be spotted in the blood after detection of HA. These antibodies may help safeguard against disease by Haemophilus influenzae, a bacterium that can create respiratory infections.

Application (Therapeutic, Research, Diagnostic)

The diagnostic segment is estimated to account for 40% of the global anti-HA antibody market share by 2036 and is anticipated to expand at the highest rate over the forecast timeline owing to the wide utilization of blood tests for diagnostic reasons like Food Allergy & intolerance testing and immunoprotein diagnostic testing among others. For instance, as of December 22, 2022, Austria had executed the most antibody tests per one million population among the countries most massively influenced by the pandemic. The U.S. has executed over 1.1 billion antibody tests in total. Countries across the globe made prevalent testing a key part of their strategies to exit lockdown. However, the international requirement for antibody test kits has been massive. The kits are implemented to recognize antibodies in a person’s blood pattern. The existence of antibodies signifies the person has been susceptible to the SARS-CoV-2 virus and created antibodies to help fight it.

Our In-Depth Analysis of the Global Market Includes the Following Segments:

          Type

  • IgM
  • IgG
  • IgA

          Application

  • Therapeutic
  • Research
  • Diagnostic

          End-Users

  • Hospitals
  • Diagnostic Centers
  • Research Institutes
  • Biopharmaceutical Companies

          Distribution Channel

  • Direct Sales
  • Distributors

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Anti-HA Antibody Industry - Regional Synopsis

North American Market

The North America anti-HA antibody market is expected to hold around 36% of the revenue share by the end of 2036. Improvements in technology, like genetic engineering and monoclonal antibody production, have promoted the growth of more powerful and particular anti-HA antibodies which will further be the main reason for the anti-HA antibody market growth of this region. For instance, multiple dozen SARS-CoV-2-distinct mAbs, Tixagevimab + Cilgavimab, Sotrovimab, Regdanvimab, Casirivimab + Imdevimab (Ronapreve), and Bebtelovimab, among others and antiviral medications (Remdesivir, Molnupiravir, and Nirmatrelvir) have been licensed and are accessible in clinical practice in the USA.

European Market Analysis

The Europe region is also predicted to notice an outstanding acceleration in the growth of the anti-HA antibody market in the predicted timeline and the increasing rate of Europeans encountering respiratory disease will wheel the growth of the market. Mortality from respiratory diseases is the third primary reason for death in EU countries, attributing to 8% of all deaths. More than 440,000 people died from respiratory diseases, a growth of 15% over the last year. Most of these fatalities (90%) were among people 65 and over than that years old. The primary reasons for death from respiratory diseases are chronic impeding pulmonary disease, pneumonia, asthma, and influenza.

Research Nester
Anti-HA Antibody Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Anti-HA Antibody Landscape

top-features-companies
    • F. Hoffmann-La Roche Ltd.
      • Company Overview
      • Business Planning
      • Main Product Offerings
      • Financial Execution
      • Main Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Johnson & Johnson
    • Merck KGaA
    • Novartis International AG
    • AbbVie Inc.
    • Amgen Inc.
    • Pfizer Inc.
    • Bayer AG
    • Eli Lilly and Company
    • Bristol-Myers Squibb Company

In-the-news

In The News

  • Pfizer Inc. and BioNTech SE released positive topline outcomes from a Phase 1/2 study (NCT05596734) analyzing the protection, acceptability, and immunogenicity of mRNA-dependent mixture vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age. The information from the investigation demonstrated that the organizations' lead preparation showed powerful immune replies to influenza A, influenza B, and SARS-CoV-2 strains.
  • Pfizer Inc. presented information across its contagious disease portfolio at IDWeek 2023 occurred in Boston from October 11-15, 2023. Information from 45 abstracts shows the developments Pfizer is making in helping stop and cure specific contagious diseases, specifically respiratory illnesses. This comprised research highlighted in the IDWeek press program analyzing the possible public health influence of ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the organization’s double respiratory syncytial virus prefusion F (RSVpreF) vaccine for motherly immunization to safeguard infants against RSV illness.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5461
  • Published Date: Dec 18, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The increasing cases of influenza flu in people worldwide will majorly drive the market growth of the anti-HA antibody market.

The market size of the anti-HA antibody market is expected to get a CAGR of approximately 7% over the forecast period, i.e., 2024-2036.

The major players in the market are F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck KGaA, Novartis International AG, AbbVie Inc., Amgen Inc., Pfizer Inc., Bayer AG, Eli Lilly and Company, Bristol-Myers Squibb Company, Daiichi Sankyo Co Ltd, Takeda Pharmaceutical Co Ltd., Chugai Pharmaceutical Co Ltd, Sanofi KK.

The IgM segment is anticipated to reap the largest market size with almost 47% by the end of 2036 and demonstrate substantial growth scopes.

The market in the North American region is expected to have the largest market share by the end of 2036 and provide more business opportunities in the future.
Anti-HA Antibody Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying